PuREC is a Shimane University spinout company having patented technologies to produce extremely purified MSC, or mesenchymal stem cells. PuREC's REC is coming from Rapidly Expanding Cells enabling to obtain 10^12 ordered pure cells within 12 weeks without requiring complicated methodologies including gene-modification.
This base-technology can be used for many types of applications including cell therapy field for orphan diseases. PuREC has been running collaborative research and joint projects with Hokkaido and Shimane Universities and Japanese corporates. PuREC is prepared for the first in-human trial for hypophosphatasia (a rare bone-formation deficiency disease for new-born babies), ready for its clinical trial in 2021. Also two other orthopaedic applications (e.g. disc herniation and joint diseases) will be in IND phase within a few years. Those three disease targets are in ongoing pipeline with challenging total $23.5bn world-wide market.
Using the same platform technology, PuREC is looking for business partners to invest on the following disease types:
GvHD (Graft-versus-host disease)
Spinal cord injury
Other joint diseases
(focusing on EU and US market)
New applications including immunology diseases
Target $10M by 2022
Target other disease target POC
Create global business development team
Global investors outside Japan are also welcome